Gastric metastasis from ovarian carcinoma is extremely rare and the prognosis for patients is poor. We report a case of multimodal treatment improving the survival time of a patient with gastric metastasis from ovarian cancer. A 73-year-old woman with known serous ovarian cancer was admitted to the hospital due to epigastric pain and dyspepsia. On esophagogastroduodenoscopy, a protruding mass was noted at the gastric antrum. She underwent distal gastrectomy with Billroth I anastomosis and lymph node dissection, including the para-aortic lymph nodes. The final pathology revealed gastric metastasis from ovarian serous adenocarcinoma. In this case, after cytoreductive surgery, chemotherapy was performed each time a recurrence was diagnosed, and remission was accomplished. She survived for 108 months after the first diagnosis of the metastatic tumor in the stomach. Multimodal treatment of metastatic lesions since the first diagnosis allowed the patient to survive longer than those in previous reports.
Introduction
The stomach is an unusual site for metastasis. Most gastric metastases are reported to arise from breast cancer, lung cancer, or melanoma. [1] [2] [3] [4] [5] Gastric metastasis from ovarian carcinoma is extremely rare because ovarian carcinoma usually metastasizes along the peritoneal surface. The presence of gastric metastasis is likely to be a preterminal event, and therefore the prognosis for patients is poor and the survival period is extremely short. Here, we report a case of multimodal treatment improving the survival of a patient with gastric metastasis from ovarian cancer.
Case Report
In March 2004, a 73-year-old woman presented to our hospital with a 3-week history of epigastric pain and dyspepsia. She had no hematemesis, melena, weight loss, or any other clinical manifestations.
Seven years previously, she had undergone cytoreductive surgery in our hospital for ovarian serous adenocarcinoma, followed by six cycles of adjuvant chemotherapy with paclitaxel and carboplatin. In July 1999, when a right adnexal mass was found on pelvic computed tomography (CT), she underwent secondary debulking cytoreductive surgery, followed by six cycles of adjuvant chemotherapy with paclitaxel and carboplatin.
In March 2000, the patient underwent third-look laparotomy that revealed no evidence of intra-abdominal disease.
In November 2000, a 4×3-cm cystic mass in the rectum was found on a CT scan, and she underwent low anterior resection with multiple metastatectomy, including partial vaginectomy. The biopsies revealed adenocarcinoma of unknown origin.
The patient underwent explorative laparotomy. A 7×5-cm isolated mass on the greater curvature of the stomach and multiple enlarged perigastric, perihepatic, celiac, and para-aortic lymph nodes were found. A distal gastrectomy with a Billroth I anastomosis and lymph node dissection, including the paraaortic lymph nodes, was performed.
The resected stomach had a protruding tumor that measured 7×5-cm with central ulceration ( Fig. 2A) . On a cut section, this white-yellow tumor was situated in the muscularis propria, and bulged into the serosa ( In March 2011, the size of the hypermetabolic mass increased (Fig. 3A) . An enhanced abdominal CT demonstrated recurrent gastric cancer with invasion to the pancreas (Fig. 3B) . On esophagogastroduodenoscopy, a normal mucosal covered mass was noted at the proximal site of the anastomosis. Biopsies revealed chronic gastritis with erosion (Fig. 3C ).
The patient received chemotherapy with capecitabine for 7 months, but the disease progressed to massive intrahepatic metastasis. Finally, she was referred to hospice care and died 3 months later. On the cut section, this white-yellow tumor is situated in the muscularis propria, and bulges into the serosa.
Discussion
Gastric metastasis from ovarian carcinoma is extremely rare.
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Ovarian carcinoma usually metastasizes to peritoneal surfaces by In this case, metastases in the liver and spleen were found 2 years after gastric surgery. It was uncertain whether these metastases originated from the metastatic tumor (in the stomach), or from the primary tumor (in the ovary). Hepatic parenchymal metastases of ovarian cancer can be divided into two groups: 1) unresectable, hematogenous hepatic parenchymal metastasis and 2) resectable, hepatic parenchymal metastasis from peritoneal seeding. Most hepatic parenchymal metastases come from peritoneal seeding. In some patients, hepatic metastases are present at the time of diagnosis (synchronous metastases), but more frequently, they represent the evolution of the disease after surgery (metachronous metastases). 8 Metastatic carcinoma to the spleen is rare. In most cases, the spleen is involved as part of a diffuse carcinomatosis and splenic metastasis reflects widespread hematogenous tumor dissemination.
Because the presence of gastric metastasis is likely to be a preterminal event, the prognosis for patients is poor, and the survival period is extremely short. The median interval between the treatment of the primary tumor and the diagnosis of a metastatic tumor in the stomach has been reported to be 16 to 78 months for a variety of primary cancers. 2 Kobayashi et al. 
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